pubmed-article:17262215 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17262215 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
pubmed-article:17262215 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
pubmed-article:17262215 | lifeskim:mentions | umls-concept:C0011923 | lld:lifeskim |
pubmed-article:17262215 | lifeskim:mentions | umls-concept:C0005919 | lld:lifeskim |
pubmed-article:17262215 | lifeskim:mentions | umls-concept:C0034595 | lld:lifeskim |
pubmed-article:17262215 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
pubmed-article:17262215 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
pubmed-article:17262215 | lifeskim:mentions | umls-concept:C1527240 | lld:lifeskim |
pubmed-article:17262215 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
pubmed-article:17262215 | lifeskim:mentions | umls-concept:C2001032 | lld:lifeskim |
pubmed-article:17262215 | pubmed:issue | 8 | lld:pubmed |
pubmed-article:17262215 | pubmed:dateCreated | 2007-8-21 | lld:pubmed |
pubmed-article:17262215 | pubmed:abstractText | We aimed at designing and developing a novel bombesin analogue, DOTA-PEG(4)-BN(7-14) (DOTA-PESIN), with the goal of labelling it with (67/68)Ga and (177)Lu for diagnosis and radionuclide therapy of prostate and other human cancers overexpressing bombesin receptors. | lld:pubmed |
pubmed-article:17262215 | pubmed:language | eng | lld:pubmed |
pubmed-article:17262215 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17262215 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17262215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17262215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17262215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17262215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17262215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17262215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17262215 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17262215 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17262215 | pubmed:month | Aug | lld:pubmed |
pubmed-article:17262215 | pubmed:issn | 1619-7070 | lld:pubmed |
pubmed-article:17262215 | pubmed:author | pubmed-author:ReubiJean... | lld:pubmed |
pubmed-article:17262215 | pubmed:author | pubmed-author:EisenhutMicha... | lld:pubmed |
pubmed-article:17262215 | pubmed:author | pubmed-author:MaeckeHelmut... | lld:pubmed |
pubmed-article:17262215 | pubmed:author | pubmed-author:WaserBeatrice... | lld:pubmed |
pubmed-article:17262215 | pubmed:author | pubmed-author:WildDamianD | lld:pubmed |
pubmed-article:17262215 | pubmed:author | pubmed-author:SchuhmacherJo... | lld:pubmed |
pubmed-article:17262215 | pubmed:author | pubmed-author:ZhangHanwenH | lld:pubmed |
pubmed-article:17262215 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17262215 | pubmed:volume | 34 | lld:pubmed |
pubmed-article:17262215 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17262215 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17262215 | pubmed:pagination | 1198-208 | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:meshHeading | pubmed-meshheading:17262215... | lld:pubmed |
pubmed-article:17262215 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17262215 | pubmed:articleTitle | DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. | lld:pubmed |
pubmed-article:17262215 | pubmed:affiliation | Division of Radiological Chemistry, Department of Radiology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. | lld:pubmed |
pubmed-article:17262215 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17262215 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17262215 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17262215 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17262215 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17262215 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17262215 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17262215 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17262215 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17262215 | lld:pubmed |